Peptide Therapies: Balancing Hype and Hope with Hard Evidence
Episode notes
On this episode, we take a break from corrections-focused medicine to talk about the emerging uses of gray market peptide therapies. While GLP-1s have enjoyed a celebrity and social media-fueled blockbuster status with their demonstrated effects on weight loss and diabetes, their unapproved peptide cousins with nebulous names like BPC-157, TB-500, and MOTS-c are growing in popularity thanks in part to wellness influencers touting them as biohacks for injury recovery, muscle growth, and more.
Chris looks at the science behind peptides as a whole and their amazing history in the annals of medicine, before focusing in on the history of the gray market agents and where the research stands on their use and supposed effectiveness. He also digs into some recent regulatory dustups that have muddied the waters for consumers.
Before that, we look at some key clinical updates:
The First mRNA Flu Vaccine
Mounjaro’s New Cardiovascular Indication
A New Single Tablet HIV Switch Option
Levetiracetam Updates
And for our trivia capsule, we revisit the history behind at the granddaddy of peptide therapies – insulin.
Link to the full show notes with references for further reading.
Sponsor Links:
Music in this Episode:
The Retro Synth by Art Haiz
Vitals & Headlines (Suno AI)
Breezy Thoughts (Suno AI)
Trivia Time Ticker (Suno AI)